Second French Trial Tragedy Verdict: No Danger Signs In Lower Dose Triallists
Executive Summary
A second committee has given its opinion on the Phase I trial tragedy in France earlier this year in which one volunteer died and four others were hospitalized after suffering neurological damage. The panel found that while some neurological signals were seen in about half of the other 80-odd volunteers, these were in line with what would be expected in a first-in-human clinical trial and differed from the lesions seen in the volunteers who were hospitalized.
You may also be interested in...
French Say Phase I Inquiry Findings To Feed Into Review Of EU First-In-Man Guidelines
The French health minister, Marisol Touraine, says that she intends to send the dossiers on the 90 volunteers who took part in the disastrous Phase I FAAH inhibitor study in Rennes to the working groups that have been set up at EU level to look into possible changes to the EU guidelines on first-in-man studies1,2.
WHO Launches Twin-Track Procedure To Speed Access To Health Products
A procedure used to accelerate the approval of COVID-19 products during the pandemic is to be applied to all medicines using “synchronized and parallel, but otherwise entirely independent, processes,” the World Health Organization says.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.